Nuclivision, a Ghent-based medtech startup, has secured €5 million from prominent investors for the rollout of its AI software platform Nuclarity, aimed at improving the efficiency and safety of PET scans.

Target Information

Nuclivision is an innovative medtech startup based in Ghent, Belgium, focused on transforming medical imaging through artificial intelligence. The company has successfully raised €5 million from esteemed investors, including LUMO Labs, Heran Partners, and the imec.istart future fund, to propel the commercial rollout of its proprietary AI software platform, Nuclarity. This platform aims to enhance the efficiency and accessibility of PET scan imaging, a critical tool in the early detection of life-threatening conditions such as cancer and Alzheimer’s disease.

Traditional PET scans, which utilize radiotracers, come with inherent costs and radiation risks that often limit patient access to these essential diagnostic procedures. By leveraging AI, Nuclivision's Nuclarity platform significantly reduces the radiation dosage and overall scanning time required for high-quality imaging, addressing both safety and economic concerns in the healthcare sector.

Industry Overview

The medical imaging industry is experiencing a transformative phase, particularly in Europe, driven by advancements in radiopharmaceuticals and theranostics. The adoption of innovative technologies such as AI is becoming indispensable as the demand for PET and SPECT sc